tiprankstipranks
Trending News
More News >

Xylem price target raised to $162 from $157 at RBC Capital

RBC Capital analyst Deane Dray raised the firm’s price target on Xylem to $162 from $157 and keeps an Outperform rating on the shares after its Q1 earnings beat. Key positives this quarter included 22% organic sales growth at Measurement and Control Solutions segment with over 550 bps of EBITDA margin expansion, book-to-bill of 1.1 times, and a 20-year build-own-operate outsourcing contract announcement with a hydrogen plant, the analyst tells investors in a research note.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue